IDEXX Laboratories Inc. (NASDAQ:IDXX) shares advanced 2.57% in pre-market trading on Monday after the veterinary diagnostics company reported stronger-than-expected third-quarter 2026 results and raised its full-year revenue and earnings guidance.
The company posted adjusted earnings of $3.96 per share, exceeding analysts’ consensus estimate of $3.72 by $0.24.
Quarterly revenue increased approximately 10% to $1.21 billion, compared with $1.11 billion in the corresponding period last year. The result also surpassed market expectations of $1.19 billion.
Growth was supported by higher recurring revenue in the company’s Companion Animal Group (CAG) Diagnostics business, increased sales of veterinary laboratory consumables and continued adoption of its diagnostic instruments.
IDEXX also reported improvements in gross and operating margins, reflecting stronger profitability alongside revenue growth.
IDEXX delivered third-quarter results ahead of market forecasts, supported by growth in its veterinary diagnostics operations.
Adjusted earnings per share reached $3.96, compared with the analyst consensus of $3.72, representing an earnings beat of approximately 6.5%.
Revenue totalled $1.21 billion, exceeding the $1.19 billion estimate by approximately $20 million.
The company reported revenue of $1.11 billion in the prior-year quarter, with the latest results representing approximately 10% year-on-year growth.
The performance reflected higher demand for diagnostic products and services used by veterinary practices, alongside continued expansion in recurring revenue.
The stronger results contributed to management’s decision to increase its financial expectations for the remainder of 2026.
The Companion Animal Group Diagnostics business remained an important contributor to IDEXX’s quarterly performance.
CAG Diagnostics recurring revenue increased 11% compared with the same period last year.
The company attributed the growth to strong volume expansion and benefits from its ongoing product innovation strategy.
Recurring diagnostics revenue includes products and services used repeatedly by veterinary practices, providing an ongoing revenue stream beyond the initial placement of diagnostic equipment.
The latest growth indicates continued demand for IDEXX’s diagnostic testing solutions within its companion animal healthcare business.
Management expects this momentum to continue through the remainder of the year, with updated guidance indicating double-digit growth in CAG Diagnostics recurring revenue.
IDEXX continued expanding the installed base of its diagnostic equipment during the third quarter.
The company placed more than 1,900 IDEXX inVue Dx analysers during the reporting period.
These placements increased the installed base to nearly 11,000 instruments.
The expansion reflects continued adoption of the company’s diagnostic technology among veterinary practices.
Instrument placements are an important component of IDEXX’s commercial strategy because diagnostic equipment can support ongoing demand for associated testing products and consumables.
The growing installed base therefore provides a foundation for recurring revenue as veterinary customers continue using the company’s diagnostic systems.
The company did not disclose a separate revenue contribution from inVue Dx placements in the information provided.
IDEXX also reported strong growth in its VetLab consumables business.
Revenue from VetLab consumables increased 14% on a reported basis during the third quarter.
On an organic basis, consumables revenue grew 15%.
The performance reflected continued demand for diagnostic testing products used with IDEXX’s laboratory equipment.
Consumables represent an important recurring revenue category because veterinary practices require ongoing supplies to operate their diagnostic instruments.
Growth in consumables revenue complemented the expansion of IDEXX’s installed equipment base and supported the broader increase in CAG Diagnostics recurring revenue.
The company attributed its overall diagnostics performance to volume growth and the contribution of new products and technologies.
President and Chief Executive Officer Mike Erickson said the third-quarter performance reflected strong commercial execution and continued progress in IDEXX’s innovation strategy.
“IDEXX delivered exceptional third quarter results, reflecting strong commercial execution and momentum from our innovation-driven growth strategy,” Erickson said.
The company’s results demonstrated growth across several important areas of its veterinary diagnostics business, including recurring revenue, consumables and instrument placements.
Management’s comments highlighted the role of product innovation in supporting customer adoption and increasing diagnostic testing activity.
The expansion of the inVue Dx installed base and continued growth in VetLab consumables were among the developments contributing to the quarter’s performance.
IDEXX reported improved profitability during the third quarter, with both gross and operating margins increasing.
Reported operating margin rose 100 basis points to 33.1%.
On a comparable basis, operating margin improved by 60 basis points.
The company also reported a 110-basis-point increase in gross margin, which reached 62.9%.
The margin improvements accompanied the increase in quarterly revenue and reflected stronger operating performance.
Higher recurring diagnostics revenue and continued sales growth supported profitability during the period.
The expansion in margins contributed to the company’s stronger earnings performance and provided additional support for its revised full-year guidance.
Following the stronger third-quarter results, IDEXX increased its full-year 2026 revenue forecast.
The company now expects annual revenue between $4.74 billion and $4.77 billion.
The midpoint of the revised range is approximately $4.75 billion, exceeding the analyst consensus estimate of $4.72 billion.
The higher forecast reflects management’s improved expectations for revenue growth during the remainder of the financial year.
IDEXX also raised its organic revenue growth outlook to a range of 9.3% to 10.0%.
The midpoint of the updated organic growth forecast represents an increase of 0.6 percentage points compared with the company’s previous guidance.
The revision follows the third quarter’s revenue growth and continued expansion in the diagnostics business.
IDEXX also raised its earnings expectations for 2026.
The company now forecasts full-year earnings per share between $14.96 and $15.16.
The revised range compares with the analyst consensus estimate of $14.88.
The midpoint of the company’s updated EPS guidance is $15.06, approximately 1.2% above the consensus forecast.
The increased earnings outlook reflects the stronger third-quarter performance and management’s expectations for continued profitability.
The company also provided updated guidance for CAG Diagnostics recurring revenue.
Reported recurring revenue in the segment is expected to increase between 11.0% and 11.7% for the full year.
The forecast indicates that IDEXX expects double-digit growth in its core recurring diagnostics operations to continue through the end of 2026.
IDEXX’s third-quarter results demonstrated continued growth in veterinary diagnostics demand, supported by increased instrument adoption and recurring consumables revenue.
Adjusted earnings of $3.96 per share exceeded expectations, while revenue increased approximately 10% to $1.21 billion.
CAG Diagnostics recurring revenue rose 11%, VetLab consumables sales increased 14% on a reported basis, and the company placed more than 1,900 inVue Dx analysers.
Profitability also improved, with operating margin reaching 33.1% and gross margin increasing to 62.9%.
The company responded by raising its full-year revenue and earnings guidance, with both revised forecasts exceeding analyst consensus estimates.
The 2.57% pre-market increase in IDEXX shares reflected a positive market response to the earnings beat and improved outlook.
Looking ahead, investors will be monitoring recurring diagnostics revenue growth, continued adoption of IDEXX’s instruments and the company’s ability to maintain its improved operating margins.
The updated guidance suggests management expects its innovation-driven growth strategy to continue supporting financial performance through the remainder of 2026.
IDEXX Laboratories stock price
| 1 hour | |
| 2 hours | |
| 3 hours | |
| 4 hours | |
| Oct-26 | |
| Oct-20 | |
| Oct-12 | |
| Oct-01 | |
| Sep-30 | |
| Sep-17 | |
| Sep-16 | |
| Sep-10 | |
| Aug-31 | |
| Aug-11 | |
| Aug-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite